Literature DB >> 23374719

The emerging role of constitutive androstane receptor and its cross talk with liver X receptors and peroxisome proliferator-activated receptor A in lipid metabolism.

Lei Xiao1, Jing Wang, Mengxi Jiang, Wen Xie, Yonggong Zhai.   

Abstract

The regulation of lipid metabolism is central to energy homeostasis in higher multicellular organisms. Lipid homeostasis depends on factors that are able to transduce metabolic parameters into regulatory events representing the fundamental components of the general control system. Nuclear receptors form a superfamily of ligand-activated transcription factors implicated in various physiological functions including energy metabolism. The constitutive androstane receptor (CAR, NR1I3), initially identified as a xenobiotic-sensing receptor, may also have roles in lipid homeostasis. The nuclear receptors liver X receptors (LXRs, NR1H2/3) and peroxisome proliferator-activated receptors (PPARs, NR1C) have been known for their roles in lipid metabolism. LXR is a sterol sensor that promotes lipogenesis, whereas PPARα controls a variety of genes in several pathways of lipid metabolism. This chapter focuses primarily on the role of CAR in lipid metabolism directly or through its cross talk with LXRs and PPARα.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23374719     DOI: 10.1016/B978-0-12-407766-9.00010-9

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  3 in total

Review 1.  Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.

Authors:  Carolina Dagli-Hernandez; Yitian Zhou; Volker Martin Lauschke; Fabiana Dalla Vecchia Genvigir; Thiago Dominguez Crespo Hirata; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-08-17       Impact factor: 3.024

2.  Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.

Authors:  Rui Lou; Haixia Cao; Shuchen Dong; Chen Shi; Xiaoyue Xu; Rong Ma; Jianzhong Wu; Jifeng Feng
Journal:  Anticancer Drugs       Date:  2019-06       Impact factor: 2.248

Review 3.  The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.

Authors:  Pengfei Xu; Yonggong Zhai; Jing Wang
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.